Antitumor Effects of HPV DNA Vaccine Adjuvanted with Beclin-1 as an Autophagy Inducer in a Mice Model

Naziri, Hamed; Tahamtan, Alireza; Dadmanesh, Maryam; Barati, Mohammad; Ghorban, Khodayar

doi:10.29252/ibj.23.6.388

Cited by 4 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Starvation is an efficient way to induce autophagy, which may subsequently result in boosted antigen presentation and/or robust T-cell responses [67]. By augmenting autophagy-mediated antigen presentation, it has been shown that a DNA vaccine could directly acquire greater efficacy [68]. The PI3K/AKT/mTOR signaling might be involved in the occurrence/development of several inflammations with dysfunctional autophagy [41,69].…”

Section: Dendritic Cells and Chitosanmentioning

confidence: 99%

Recent Progress of Chitosan Nanoparticles for the Development of Superior Delivery of Vaccines

Nakashima,

Suga,

Ikeda

et al. 2024

Discovery Medicine

View full text Add to dashboard Cite

Chitosan seems to be an innovative biological material potentially utilized as a nanoparticle carrier for drug delivery, which could be low toxic, biocompatible, and easy to prepare. Chitosan nanoparticles have been employed in gene delivery. As a type of multifunctional adjuvant, chitosan nanoparticles could activate the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway to induce cell protection and/or proliferation via the modulation of autophagy within dendritic cells. In general, adjuvants may improve the innate and/or adaptive immune responses to a vaccine antigen by facilitating the antigen presentation of antigen presenting cells such as dendritic cells. The choice of a suitable adjuvant has become vital for improved safety and/or expanded application of vaccines. Fortunately, chitosan nanoparticles could be designed to target the dendritic cells to be enhanced by its adjuvant effect and for stimulating robust immune responses. Therefore, chitosan nanoparticles may be a good immune stimulant with encouraging properties for the development of superior vaccine delivery. Indeed, vaccines could play a key role in human health. In this review, we summarize the concept and/or recent progress in the field of chitosan nanoparticles, providing a valuable resource for investigating the molecular mechanisms of chitosan for the development of a greater vaccine.

show abstract

Section: Dendritic Cells and Chitosanmentioning

confidence: 99%

Recent Progress of Chitosan Nanoparticles for the Development of Superior Delivery of Vaccines

Nakashima,

Suga,

Ikeda

et al. 2024

Discovery Medicine

View full text Add to dashboard Cite

show abstract

“…Exploratory studies of novel adjuvants used alone or in combination have highlighted their potential use in HPV vaccines ( Table 4 ). Bacterial-derived components, such as Beclin-1 ( 105 ), AS04 (NLX+Alum) ( 25 ), CIA06B (nontoxic derivative of lipopolysaccharide (CIA05) + Alum) ( 100 ), rough LPS (R-LPS) ( 98 ), and bacterial enzymatic combinatorial chemistry (BECC)-derived TLR4 agonists/Alum ( 70 ), are widely utilized in exploratory studies.…”

Section: Future Directions For Hpv Vaccine Developmentmentioning

confidence: 99%

Current status and future directions for the development of human papillomavirus vaccines

Wang,

Huang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The development of human papillomavirus (HPV) vaccines has made substantive progress, as represented by the approval of five prophylactic vaccines since 2006. Generally, the deployment of prophylactic HPV vaccines is effective in preventing newly acquired infections and incidences of HPV-related malignancies. However, there is still a long way to go regarding the prevention of all HPV infections and the eradication of established HPV infections, as well as the subsequent progression to cancer. Optimizing prophylactic HPV vaccines by incorporating L1 proteins from more HPV subtypes, exploring adjuvants that reinforce cellular immune responses to eradicate HPV-infected cells, and developing therapeutic HPV vaccines used either alone or in combination with other cancer therapeutic modalities might bring about a new era getting closer to the vision to get rid of HPV infection and related diseases. Herein, we summarize strategies for the development of HPV vaccines, both prophylactic and therapeutic, with an emphasis on the selection of antigens and adjuvants, as well as implications for vaccine efficacy based on preclinical studies and clinical trials. Additionally, we outline current cutting-edge insights on formulation strategies, dosing schedules, and age expansion among HPV vaccine recipients, which might play important roles in addressing barriers to vaccine uptake, such as vaccine hesitancy and vaccine availability.

show abstract

“…4 HPV also contributes to the accumulation of suppressive immune cells, such as bone marrow-derived suppressor cells (MDSCs) and regulatory T (Treg) cells, and forms an immunosuppressive tumor microenvironment (TME) during tumourigenesis and development. 5 In addition, HPV knockout can induce autophagy, [6][7][8] and the downregulation of HPV function can effectively support the occurrence of cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

“…First, hu-PBL-SCID mice were inoculated subcutaneously with ∼2 × 10 6 SiHa tumor cells on the right limb and then treated intravenously on Days 4, 7, and 10 with PBS, control gRNA, control liposome, or HPV gRNA-liposome. Some HPV gRNA-liposome-treated mice also received an intraperitoneal injection of anti-PD-1 (100 μg per mouse, 100 μl) onDays 5,8,and 11…”

mentioning

confidence: 99%

CRISPR/Cas9‐HPV‐liposome enhances antitumor immunity and treatment of HPV infection‐associated cervical cancer

Zhen

Qiang

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Increasing evidence shows that human papillomavirus (HPV) E6/E7 deletion in cervical cancer cells may be related to the immunosuppressive tumor microenvironment and adverse reactions or resistance to immune checkpoint blockade. Here, we demonstrate that liposome delivery of CRISPR/cas9 can effectively knock out HPV, which, in turn, induces autophagy and triggers cell death‐related immune activation by releasing damage‐related molecular patterns. The results of in vivo experiments showed that HPV‐targeting guide RNA–liposomes could promote CD8+ T cell infiltration in tumor tissues; enhance the expression of proinflammatory cytokines, such as interleukin‐12, tumor necrosis factor‐α, and interferon‐γ, and reduce regulatory T cells and myeloid suppressor cells. The combination of HPV‐targeting guide RNA–liposomes with immune checkpoint inhibitors and antiprogrammed death‐1 antibodies produced highly effective antitumor effects. In addition, combination therapy induced immune memory in the cervical cancer model.

show abstract

Antitumor Effects of HPV DNA Vaccine Adjuvanted with Beclin-1 as an Autophagy Inducer in a Mice Model

Cited by 4 publications

References 36 publications

Recent Progress of Chitosan Nanoparticles for the Development of Superior Delivery of Vaccines

Recent Progress of Chitosan Nanoparticles for the Development of Superior Delivery of Vaccines

Current status and future directions for the development of human papillomavirus vaccines

CRISPR/Cas9‐HPV‐liposome enhances antitumor immunity and treatment of HPV infection‐associated cervical cancer

Contact Info

Product

Resources

About